Our data uncovered that KLF13 directly bound to the SH2B1 promoter to restrain its transcription and expression, thereby inhibiting glycolysis to delay progression of NSCLC in vitro and in vivo. Here, SH2B1 is linked to non-small cell lung carcinoma.